Premium
[O2‐01‐08]: Therapeutic effects of intranasal insulin in patients with AD and amnestic MCI
Author(s) -
Craft Suzanne,
Reger Mark,
Watson G. Stennis,
Plymate Steven,
Fishel Mark,
Frey William,
Baker Laura,
Cholerton Brenna,
Rhoads Kristoffer
Publication year - 2005
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2005.06.333
Subject(s) - insulin , medicine , hyperinsulinemia , nasal administration , insulin resistance , hypoglycemia , saline , placebo , endocrinology , pharmacology , alternative medicine , pathology
ments for age, sex, and APOE. Vitamin E users who had a history of stroke (HR 3.18, 95% CI 1.32-7.68), coronary artery bypass graft (HR 5.00, 95% CI 3.21-7.78), or myocardial infarction (HR 1.97, 95% CI 1.26-3.07) had increased mortality risks. Similarly, participants taking vitamin E and nitrates were at significantly increased risk of death (HR 5.96, 95% CI 3.04-11.69) after adjustments. When we adjusted for nitrates, the risk associated with cardiovascular events was no greater in vitamin E users than non-users. An interaction was found between vitamin E, coumadin, and nitrates used in combination. A portion of this interaction was independent of coumadin use. Conclusions: Regular use of vitamin E ( 400IU) does not increase the risk of mortality in healthy individuals aged 65 . Vitamin E supplementation does, however, increase the risk of mortality in those with severe CVD, possibly due to medication interactions. We identified interactions between vitamin E, nitrates, and coumadin. It appears the increased risk of mortality associated with vitamin E use in persons with severe CVD can be accounted for by these interactions although disease by vitamin E interaction cannot be ruled out.